FDA Extends Review of Exelixis' Colorectal Cancer Drug
The US Food and Drug Administration has extended its review period for Exelixis' zanzalintinib, a treatment for colorectal cancer, by three months. The delay caused Exelixis stock to fall as investors awaited further regulatory clarity.